October 25, 2026 02:04 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Jamia shifts classes online after clash over demand for student union polls; Congress MPs face allegations | Deadly mid-air collision: Four pilots killed as two military aircraft crash in Philippines | ‘Jihad’ calls, Modi assassination remarks: Mumbai Rapido driver arrested over alleged Jaish links | Vegetarian-only kitchen at Keralam Lok Bhavan? Governor's reported order triggers political backlash | ‘Another little Epic Fury’: Trump’s chilling warning to Iran as fresh US strikes loom | Bomb threat email names Amitabh Bachchan’s Jalsa bungalow, Diljit Dosanjh’s concert venue: Reports | ‘Face-offs still continue’: ITBP chief reveals fresh India-China border tensions in Arunachal | Eiffel Tower women staff row: BAPS monk blames ‘miscommunication’, denies delegation's role | ‘Pen, not stones and guns’: RSS-linked group opens its first office in Kashmir Valley under Muslim leader | First human case of Shamonda virus reported in France; WHO confirms death of immunocompromised patient
Image credit: UNI

CCI green lights Nirma Ltd's acquisition of Glenmark Life Sciences

| @indiablooms | Dec 20, 2023, at 05:07 am

New Delhi: The Competition Commission of India (CCI) on Tuesday gave its nod to Nirma Limited to acquire the majority shares of Glenmark Life Sciences Limited.

Nirma Limited plans to acquire these shares by purchasing them from Glenmark Life Sciences' promoter and from public shareholders through an open offer, the antitrust watchdog said in a statement.

Nirma Limited has a diverse presence and operations in India and the USA, involved in various products such as soda ash, soaps, detergents, salt, caustic soda, Linear Alkyl Benzene, and other industrial items.

On the other hand, Glenmark Life Sciences is primarily involved in the development, manufacturing, and sale of Active Pharmaceutical Ingredients (APIs) and intermediaries.

It also provides contract development and manufacturing organization (CDMO) services for APIs.

The company's portfolio includes over 130 APIs catering to chronic therapeutic segments like cardiovascular disease, central nervous system disorders, pain management, and anti-diabetics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.